Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-25T12:42:57.663Z Has data issue: false hasContentIssue false
  • English
  • Français

The time course of the humoral immune response to rhinovirus infection

Published online by Cambridge University Press:  15 May 2009

W. S. Barclay ,
W. Al-Nakib ,
P. G. Higgins  and
D. A. J. Tyrrell
W. S. Barclay*
Affiliation:
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wilts, SP2 8BW Department of Microbiology, University of Reading, London Road, Reading, Berks RG1 5AQ
W. Al-Nakib
Affiliation:
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wilts, SP2 8BW Department of Microbiology, Faculty of Medicine, University of Kuwait
P. G. Higgins
Affiliation:
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wilts, SP2 8BW
D. A. J. Tyrrell
Affiliation:
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wilts, SP2 8BW
*
*present address at Reading.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The specific humoral immune response of 17 volunteers to infection with human rhinovirus type 2 (HRV-2) has been measured both by neutralization and by ELISA. Six volunteers who had HRV-2-specific antibodies in either serum or nasal secretions before HRV-2 inoculation were resistant to infection and illness. Of the remaining 11 volunteers who had little pre-existing HRV-2-specific antibody, one was immune but 10 became infected and displayed increases in HRV-2-specific antibodies. These antibodies first increased 1–2 weeks after infection and reached a maximum at 5 weeks. All six resistant volunteers who had high pre-existing antibody and eight of the volunteers who became infected maintained their HRV-2-specific antibody for at least 1 year. At this time they were protected against reinfection. Two volunteers showed decreases in HRV-2-specific antibodies from either serum or nasal secretions. They became infected but not ill after HRV-2 inoculation 1 year later.

Type
Research Article
Information
Epidemiology & Infection , Volume 103 , Issue 3 , December 1989 , pp. 659 - 669
Copyright
Copyright © Cambridge University Press 1989

References

REFERENCES

1.Couch, RB.The common cold: control? J Infect Dis 1984; 150: 167–73.CrossRefGoogle ScholarPubMed
2.Taylor-Robinson, D.Studies on some viruses (rhinoviruses) isolated from common colds. Arch Virusforsch 1963; 13: 281–93.CrossRefGoogle ScholarPubMed
3.Cate, TR, Couch, RB, Johnson, KM.Studies with rhinoviruses in volunteers: production of illness, effect of naturally acquired antibody and demonstration of a protective effect not associated with serum antibody. J Clin Invest 1964; 43: 56–67.CrossRefGoogle Scholar
4.Cate, TR, Rossen, RD, Douglas, A Jr, Butter, WT, Couch, RB.The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol 1966; 84: 352–63.CrossRefGoogle ScholarPubMed
5.Bynoe, ML, Hobson, D, Homer, J et al. Inoculation of human volunteers with a strain of virus isolated from a common cold. Lancet 1961; 1: 1194–6.CrossRefGoogle ScholarPubMed
6.Perkins, JC, Tucker, DN, Knopf, NLS et al. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol 1969; 90; 519–26.CrossRefGoogle ScholarPubMed
7.Hendly, JO, Gwaltney, JM, Jordan, WS JrRhinovirus infections in an industrial population. iv. infections within families of employees during two fall peaks of respiratory illness. Am J Epidemiol 1969; 89: 184–96.CrossRefGoogle Scholar
8.Barclay, WS, Callow, KA, Sergeant, M, Al-Nakib, W.The evaluation of an enzyme linked immunosorbent assay which measures rhinovirus specific antibodies in human sera and nasal secretions. J Med Virol 1988; 25: 475–82.CrossRefGoogle ScholarPubMed
9.Hamparian, VV, Leagus, MB, Hilleman, MR, Stokes, J JrEpidemiologic investigations of rhinovirus infections. Proc Soc Exp Biol Med 1964; 11: 469–76.CrossRefGoogle Scholar
10.Stott, EJ, Grist, NR, Eadie, MB.Rhinovirus infections in chronic bronchitis: isolation of eight possibly new rhinovirus serotypes. J Med Microbiol 1968; 1: 109–18.CrossRefGoogle Scholar
11.Buscho, RF, Perkins, JC, Knopf, HLS et al. Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. J Immunol 1972; 108: 169–77.CrossRefGoogle ScholarPubMed
12.Barclay, WS, Al-Nakib, W.An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion. J Virol Meth 1987; 15: 53–64.CrossRefGoogle ScholarPubMed
13.Hendley, JO.Rhinovirus colds: immunology and pathogenesis. Eur Resp Dis 1983; 128: 340–4.Google ScholarPubMed
14.Beare, AS, Reed, SE. The study of autiviral compounds in volunteers. In Oxford, J, ed. Chemoprophylaxis and virus infections of the respiratory tract. vol. 2. Cleveland: CRC Press 1987: 27–55.Google Scholar
15.Fleet, WF, Couch, RB, Cate, TR, Knight, V.Homologous and heterologous resistance to rhinovirus common cold. Am J Epidemiol 1965; 82: 185–96.CrossRefGoogle ScholarPubMed
16.Sherry, B, Rueckert, R.Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol 1985; 53: 137–43.CrossRefGoogle ScholarPubMed
17.Acornley, JE, Chapple, PJ, Stott, EJ, Tyrrell, DAJ.Selection of variants of rhinoviruses. Arch Virusforsch 1968; 23: 284–7.CrossRefGoogle ScholarPubMed
18.Holmes, MJ, Reed, SE, Stott, EJ, Tyrrell, DAJ.Studies of experimental rhinovirus type 2 infections in polar isolation and in England.J Hyg 1976; 76: 379–93.CrossRefGoogle ScholarPubMed